BB Biotech Ventures III

Please find a more detailed description of share classes here.

Investment Focus

Venture Capital Fund focusing on emerging healthcare companies that develop and market drugs and medical devices. BB BIOTECHVENTURES II was founded in 2005, BB BIOTECHVENTURES III was found in 2008. For further information please contact us under following address: Bellevue Asset Management AG Seestrasse 16 8700 Kusnacht/Zurich Tel. +41 (0)44 267 67 00 Fax +41 (0)44 267 67 01

  • Investment Advisor

    Martin Münchbach

    Dr. Martin Münchbach joined Bellevue Asset Management in 2004 as senior investment advisor private equity for the biotechnology sector. He had spent the previous 5 years with NMT und HBM BioVentures/BioMedinvest as an investment manager of venture capital. From 1998 to 1999 Martin Münchbach was engaged in strategic marketing at Sanofi-Synthélabo. He studied biochemistry at Eberhard Karls University in Tübingen and ETH Zurich (degree with distinction) and earned a PhD in protein chemistry from the ETH Zurich. He also holds a master’s degree in industrial engineering and management from ETH Zurich
  • Investment Advisor

    Klaus Breiner

    Dr. Klaus Breiner joined the private equity team of Bellevue Asset Management in 2004. He previously held positions as a venture capital investment manager at Global Life Science Ventures and as a management consultant at Booz Allen Hamilton. From 1995 to 2000, he conducted research at the Swiss Federal Institute of Technology in Zurich and at the Center for Molecular Biology (ZMBH) at the University of Heidelberg in Germany. Dr. Klaus Breiner earned a degree in chemistry from the University of North Carolina, USA, and a doctorate in molecular biology from the University of Heidelberg.
  • Investment Advisor

    Dominik Escher

    Dr. Dominik Escher, former founder & CEO of ESBATech, a Swiss biotech company focused on next-generation antibody drugs, joined Bellevue Asset Management in 2017 as Senior Investment Advisor Private Equity. Alcon had acquired ESBATech in 2009 for USD 589 million. Subsequently, Dominik Escher was VP R&D of Alcon and until 2016 a member of Global Ophthalmology Leadership and Global Biologics Leadership at Novartis. Since 2013, he has served as President of the Swiss Biotech Association. He holds a PhD in molecular biology.
  • Investment Advisor

    Anja Harmeier

    Dr. Anja Harmeier has been with Bellevue Asset Management as an Investment Advisor of BB Pureos Bioventures since 2020. Until then, she worked as Investment Director at Roche Venture Fund and as Project Manager Discovery Rare Disease at Hoffmann-La Roche. She received her PhD in Neurology and Biochemistry from the Freie Universität of Berlin.
  • Analyst

    Ximing Ding

    Dr. Ximing Ding has been part of the BB Pureos Bioventures investment team at Bellevue Asset Management since 2018. He previously worked as an analyst at IMS Health (IQVIA). After studying molecular biology at the Swiss Federal Institute of Technology (ETH) Zurich, he earned his PhD at EMBL Heidelberg, Germany.